Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Leuk Res ; 37(12): 1616-21, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24183830

ABSTRACT

CD200 is a relatively ubiquitously expressed molecule that plays a role in cancer immune evasion through interaction with its receptors. High expression levels of CD200 have been described in different human malignancies. For example, CD200 has been shown to be targeted after RAS/RAF/MEK/ERK activation in melanoma. Here we present the analysis of CD200 expression in human Multiple Myeloma (MM) samples. We found that CD200-positive cells express ERK and p-ERK. Moreover, UO126, a MEK inhibitor, reduces CD200 expression. Furthermore, we observe that CD200-positive cells show reduced immunogenicity compared to normal lymphocytes and that such immunogenicity increases when UO126 is used. We therefore hypothesize that CD200 expression in MM could suppress antitumor response and that anti-CD200 treatment might be therapeutically beneficial in CD200-expressing tumors.


Subject(s)
Antigens, CD/metabolism , Multiple Myeloma/metabolism , Antigens, Surface/metabolism , Biomarkers, Tumor/metabolism , Butadienes/pharmacology , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/metabolism , Cells, Cultured , Enzyme Inhibitors/pharmacology , Humans , Lymphocyte Activation/drug effects , Lymphocyte Culture Test, Mixed , MAP Kinase Signaling System/drug effects , MAP Kinase Signaling System/physiology , Multiple Myeloma/immunology , Multiple Myeloma/pathology , Nitriles/pharmacology , Orexin Receptors , Receptors, Cell Surface/metabolism , Tumor Escape/physiology
2.
Crit Rev Oncol Hematol ; 81(3): 207-23, 2012 Mar.
Article in English | MEDLINE | ID: mdl-21511492

ABSTRACT

Breast cancer is a clinically heterogeneous and complex disease that can affect differently individuals with seemingly identical clinicopathologic parameters. This heterogeneity is strictly linked to individuals and tumors genetic variability. Currently, the development of high-throughput technologies are proving novel tools to tackle this complexity. By DNA microarray technology, genomic analysis has been used successfully for breast carcinomas stratification into molecular subgroups with relevant implications for clinical outcomes, and detection of prognostic/treatment predictive signatures. Indeed, DNA microarray has rapidly improved becoming a powerful diagnostic tool. Information derived from these assays allows clinicians to estimate the risk for distant recurrence, and predict accurately which patients are likely to benefit from adjuvant therapy. This review will describe the state-of-the-art of genomic analysis in breast cancer and introduce the clinicians to a genomic approach to cancer management, illustrating how it can help in defying a better diagnosis, prognosis and therapeutic treatment.


Subject(s)
Breast Neoplasms/genetics , Genetic Variation , Genome-Wide Association Study/methods , Oligonucleotide Array Sequence Analysis/methods , Breast Neoplasms/diagnosis , Breast Neoplasms/therapy , Female , Humans
3.
Hum Pathol ; 42(2): 254-68, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21106223

ABSTRACT

Reduced-intensity conditioning regimens have reshaped the clinical presentation of graft-versus-host disease after hematopoietic stem cell transplants. However, histopathologic features of graft-versus-host disease following reduced-intensity conditioning regimens have not been fully characterized. In a series of 112 biopsies (skin, n = 60; gastrointestinal [GI] tract, n = 44; liver, n = 8), we described the morphologic profile of graft-versus-host disease following reduced-intensity conditioning and investigated whether histopathologic changes of graft-versus-host disease following reduced-intensity conditioning have a diagnostic and/or prognostic value. Forty-four patients (49.5%) experienced acute graft-versus-host disease, 2 (2.2%) late-onset acute graft-versus-host disease (grade I, n = 13; grade II-IV, n = 33), 24 (27.0%) chronic graft-versus-host disease (de novo n = 12, progressive n = 12) and 19 (21.3%) overlap syndrome. In the skin, we observed: (i) phase-nonspecific changes, such as acute graft-versus-host disease features in chronic graft-versus-host disease patients (n = 4/24; 16.6%), (ii) subtle alterations such as superficial fibrosis in widened dermal papillae (n = 8), in acute graft-versus-host disease/late-onset graft-versus-host disease (n = 6/46; 13.0%) or chronic graft-versus-host disease (n = 2/24, 8.3%) patients, and (iii) features of chronic and acute graft-versus-host disease coexisting in the same specimen in overlap syndrome (n = 3/19; 15.7%). In the GI tract, we did not demonstrate peculiar features differing from those commonly observed in the myeloablative setting. By univariate analysis, a reduced overall survival was associated with graft-versus-host disease type (chronic graft-versus-host disease P = .006, acute graft-versus-host disease P = .03), older age (P = .04), and histopathologic diagnosis of "consistent with" + definite graft-versus-host disease (P = .02). Histopathologic diagnosis retained an independent prognostic value by multivariate analysis (P = .01). The present study indicates that pathologists should be aware of the peculiar morphologic changes of cutaneous graft-versus-host disease following reduced-intensity conditioning and further recommends histopathology in the diagnostic workup of graft-versus-host disease in patients undergoing reduced-intensity conditioning regimen.


Subject(s)
Bone Marrow Transplantation/pathology , Graft vs Host Disease/pathology , Hematopoietic Stem Cell Transplantation , Transplantation Conditioning , Adult , Aged , Bone Marrow Transplantation/immunology , Female , Graft vs Host Disease/immunology , Graft vs Host Disease/mortality , Humans , Male , Middle Aged , Prognosis , Survival Rate , Young Adult
4.
Leuk Res ; 35(1): 52-60, 2011 Jan.
Article in English | MEDLINE | ID: mdl-20674018

ABSTRACT

Several reports demonstrated that the activation of Nuclear Factor-kappa B NF-κB is essential for the pathogenesis of multiple myeloma (MM). We analyzed the nuclear localization of NF-κB in MM-cells derived from 60 different patients with MM at presentation and in relapse, as well as in three myeloma cell lines. Nuclear localization (the active form) of NF-κB was detected in only one MM-sample from a refractory patient and in two samples from relapsed patients, while all the other samples, including the MM-cell lines, almost exclusively express the cytoplasmic (inactive) form of NF-κB. In mesenchymal cells from MM-patients NF-κB was clearly present in the nucleus. In addition, the proteasome inhibitor Bortezomib, which is described to antagonize NF-κB activity, had a consistent antitumor activity against both chemoresistant and chemosensitive MM-cells, regardless the NF-κB localization, thus suggesting the existence of other molecular targets of proteasome inhibitors in MM.


Subject(s)
Mesoderm/metabolism , Multiple Myeloma/metabolism , NF-kappa B/metabolism , Plasma Cells/metabolism , Antineoplastic Agents/pharmacology , Blotting, Western , Boronic Acids/pharmacology , Bortezomib , Cell Line, Tumor , Flow Cytometry , Humans , Immunohistochemistry , Mesoderm/pathology , Multiple Myeloma/pathology , Pyrazines/pharmacology
5.
Tumori ; 93(2): 220-2, 2007.
Article in English | MEDLINE | ID: mdl-17557576

ABSTRACT

Myoepithelial hamartoma is a very rare submucosal tumor of the stomach. Magnus-Alsleben first described 5 cases of this tumor in 1903. More recently (1993) Vandelli et al. published a review of the literature comprising only 33 cases. Histologically, the tumor is characterized by hypertrophic smooth muscle bands surrounding diverse epithelial elements that can be arranged in different ways: as a simple glandular structure, Brunner's gland, pancreatic ducts and occasionally pancreatic acinus. We report a case of myoepithelial hamartoma of the stomach simulating a gastric carcinoma.


Subject(s)
Hamartoma/diagnosis , Stomach Neoplasms/diagnosis , Aged , Diagnosis, Differential , Epithelium/pathology , Hamartoma/pathology , Humans , Male , Muscle, Smooth/pathology , Stomach Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...